Investor Centre

Pharmaxis has been granted a trading halt by the ASX. Over the weekend the Company received advice from Boehringer Ingelheim (BI) concerning its future development plans for the lead drug (BI1467335) which Pharmaxis sold to BI in 2015. The advice requires analysis by Pharmaxis senior management and directors. The trading halt is necessary to assist Pharmaxis in managing its continuous disclosure obligations. Pharmaxis requested that the trading halt remain in place until the earlier of commencement of normal trading on Wednesday, 18 December 2019, or when Pharmaxis makes an announcement concerning the advice received from BI.